Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]
News [3134]
Articles [127]
Editorials [3]
Conferences [119]
elearning [13]
How is minimal residual disease managed in patients with ALL?
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
How is minimal residual disease managed in patients with ALL? ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
BLAST: Blinatumomab for minimal residual disease in patients with ALL ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
Frontline therapy of ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
Treatment of Ph-negative ALL in adolescents and young adults
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Treatment of Ph-negative ALL in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The new era of ALL treatment ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
Safety considerations for inotuzumab in patients with relapsed/refractory ALL
Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol...
Safety considerations for inotuzumab in patients with relapsed/refractory ALL ( Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
23 Jan 2020
Identifying cancer susceptibility genes in paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Identifying cancer susceptibility genes in paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Defining high-risk acute lymphoblastic leukaemia
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Defining high-risk acute lymphoblastic leukaemia ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Latest concepts in frontline therapy for paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Latest concepts in frontline therapy for paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Are remissions for AML patients 'better' after daunorubicin and cytarabine...
Prof Daniel Ryan - University of Rochester, Rochester, USA
Are remissions for AML patients 'better' after daunorubicin and cytarabine liposome injection ( Prof Daniel Ryan - University of Rochester, Rochester, USA )
24 Dec 2019
Is enasidenib plus azacitidine better than with azacitidine alone for AML...
Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients? ( Dr Courtney DiNardo - MD Anderson Cancer Center, Houston, USA )
24 Dec 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation